ECSP13012629A - COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR 2/3 - Google Patents

COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR 2/3

Info

Publication number
ECSP13012629A
ECSP13012629A ECSP13012629A ECSP13012629A EC SP13012629 A ECSP13012629 A EC SP13012629A EC SP13012629 A ECSP13012629 A EC SP13012629A EC SP13012629 A ECSP13012629 A EC SP13012629A
Authority
EC
Ecuador
Prior art keywords
phenylsulphanylme
mglur
antagonists
hexane
substituted
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Charles Howard Mitch
Renhua Li
Stephon Cornell Smith
Tatiana Natali Vetman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45099188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012629(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP13012629A publication Critical patent/ECSP13012629A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/18All rings being cycloaliphatic the ring system containing six carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ECSP13012629 2010-11-18 2013-05-17 COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR 2/3 ECSP13012629A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41512110P 2010-11-18 2010-11-18

Publications (1)

Publication Number Publication Date
ECSP13012629A true ECSP13012629A (es) 2013-07-31

Family

ID=45099188

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012629 ECSP13012629A (es) 2010-11-18 2013-05-17 COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR 2/3

Country Status (36)

Country Link
US (1) US8629169B2 (zh)
EP (1) EP2640697B1 (zh)
JP (1) JP5877847B2 (zh)
KR (2) KR20130101094A (zh)
CN (1) CN103228625B (zh)
AR (1) AR083845A1 (zh)
AU (1) AU2011329076B2 (zh)
BR (1) BR112013012118A2 (zh)
CA (1) CA2818116C (zh)
CL (1) CL2013001345A1 (zh)
CO (1) CO6761385A2 (zh)
CR (1) CR20130178A (zh)
DK (1) DK2640697T3 (zh)
DO (1) DOP2013000099A (zh)
EA (1) EA021724B1 (zh)
EC (1) ECSP13012629A (zh)
ES (1) ES2650139T3 (zh)
GT (1) GT201300126A (zh)
HR (1) HRP20171649T1 (zh)
HU (1) HUE037457T2 (zh)
IL (1) IL225843A (zh)
LT (1) LT2640697T (zh)
MA (1) MA34663B1 (zh)
MX (1) MX339973B (zh)
NO (1) NO2640697T3 (zh)
NZ (1) NZ609816A (zh)
PE (1) PE20140997A1 (zh)
PL (1) PL2640697T3 (zh)
PT (1) PT2640697T (zh)
RS (1) RS56535B1 (zh)
SG (1) SG189959A1 (zh)
SI (1) SI2640697T1 (zh)
TW (1) TWI520935B (zh)
UA (1) UA110039C2 (zh)
WO (1) WO2012068067A1 (zh)
ZA (1) ZA201302918B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079343A1 (es) * 2009-12-21 2012-01-18 Lilly Co Eli Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
KR102444718B1 (ko) 2016-04-18 2022-09-16 다이쇼 세이야꾸 가부시끼가이샤 아미노산 유도체의 전구약물
JP2020506895A (ja) 2017-01-17 2020-03-05 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System インドールアミン2,3−ジオキシゲナーゼおよび/またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物
EP3823604A4 (en) * 2018-07-17 2022-03-16 Board of Regents, The University of Texas System COMPOUNDS USEFUL AS INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE INHIBITORS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0669928B2 (ja) 1987-10-06 1994-09-07 宇部興産株式会社 光重合性歯科材料
JP2589812B2 (ja) 1989-07-05 1997-03-12 松下電器産業株式会社 スチームアイロン
WO1997017950A1 (en) * 1995-11-16 1997-05-22 Eli Lilly And Company Shoulder prosthesis
ZA969485B (en) 1995-11-16 1998-05-12 Lilly Co Eli Excitatory amino acid receptor antagonists.
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
SK13532000A3 (sk) 1998-03-17 2002-07-02 Pfizer Products Inc. Bicyklo [2.2.1] heptány a príbuzné zlúčeniny, farmaceutické kompozície a spôsoby liečenia na ich báze
GB9815542D0 (en) 1998-07-17 1998-09-16 Lilly Co Eli Bicyclohexane derivatives
CH694053A5 (de) 1998-09-03 2004-06-30 Hoffmann La Roche Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
RU2315622C2 (ru) 2001-12-27 2008-01-27 Тайсо Фармасьютикал Ко.,Лтд. Производные 6-фторбицикло[3.1.0]гексана
PT1517915E (pt) * 2002-06-11 2009-04-09 Lilly Co Eli Pró-drogas de amino ácidos de excitação
DE602004030007D1 (en) 2003-06-26 2010-12-23 Taisho Pharmaceutical Co Ltd 2-aminobicyclo 3.1.0 hexan-2,6-dicarbonsäureesterderivat
JP4984529B2 (ja) * 2003-06-26 2012-07-25 大正製薬株式会社 2−アミノビシクロ[3.1.0]ヘキサン−2,6−ジカルボン酸誘導体
JP2007063129A (ja) 2003-06-26 2007-03-15 Taisho Pharmaceut Co Ltd 2−アミノ−3−アルコキシビシクロ[3.1.0]ヘキサン誘導体
AR079343A1 (es) * 2009-12-21 2012-01-18 Lilly Co Eli Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico

Also Published As

Publication number Publication date
WO2012068067A1 (en) 2012-05-24
CA2818116A1 (en) 2012-05-24
MA34663B1 (fr) 2013-11-02
IL225843A (en) 2015-05-31
ES2650139T3 (es) 2018-01-17
MX2013005622A (es) 2013-07-05
KR20130101094A (ko) 2013-09-12
US8629169B2 (en) 2014-01-14
PE20140997A1 (es) 2014-08-25
DK2640697T3 (en) 2017-10-23
EA201390498A1 (ru) 2013-07-30
TW201307271A (zh) 2013-02-16
BR112013012118A2 (pt) 2016-09-27
TWI520935B (zh) 2016-02-11
MX339973B (es) 2016-06-20
NZ609816A (en) 2014-12-24
SG189959A1 (en) 2013-06-28
JP2014505664A (ja) 2014-03-06
EP2640697B1 (en) 2017-09-20
CL2013001345A1 (es) 2013-11-15
ZA201302918B (en) 2014-10-29
NO2640697T3 (zh) 2018-02-17
IL225843A0 (en) 2013-06-27
RS56535B1 (sr) 2018-02-28
KR20150140876A (ko) 2015-12-16
UA110039C2 (xx) 2015-11-10
AU2011329076B2 (en) 2015-03-12
CN103228625B (zh) 2014-12-03
HRP20171649T1 (hr) 2017-12-15
EP2640697A1 (en) 2013-09-25
US20120129902A1 (en) 2012-05-24
AU2011329076A1 (en) 2013-05-02
CA2818116C (en) 2016-04-05
DOP2013000099A (es) 2013-08-15
CR20130178A (es) 2013-07-09
SI2640697T1 (sl) 2017-11-30
GT201300126A (es) 2014-02-27
JP5877847B2 (ja) 2016-03-08
AR083845A1 (es) 2013-03-27
PT2640697T (pt) 2017-12-11
CO6761385A2 (es) 2013-09-30
EA021724B1 (ru) 2015-08-31
LT2640697T (lt) 2018-01-10
CN103228625A (zh) 2013-07-31
HUE037457T2 (hu) 2018-08-28
PL2640697T3 (pl) 2018-02-28

Similar Documents

Publication Publication Date Title
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
DOP2012000135A (es) Compuestos de espiropiperidina como antagonistas del receptor orl-1
CR20150370A (es) Compuestos antivirales
UY35257A (es) Picolinamidas macrocíclicas como fungicidas, composiciones y metodos para el control de enfermedades vegetales
UY33735A (es) Compuestos antivirales
CR20150271A (es) Peptidos como agonistas de oxitocina
EP2721011A4 (en) EP2 RECEPTOR ANTAGONISTS OF PROSTAGLANDINS, DERIVATIVES, COMPOSITIONS AND USES THEREOF
CR20140435A (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
CR20150267A (es) 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il] 1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona como un antagonista del receptor ampa dependiente de tarp-gamma 8
CO6761385A2 (es) Compuestos 3-fenilsulfanilmetil-biciclo[3.1.0]hexano 4-sustituidos como antagonistas de mglur 2/3
GT201200328A (es) Intermedios de agomelatina y método de preparación de éstos
HK1207855A1 (zh) 取代的氨基甲酸酯化合物及其作為瞬時型感受器電位 通道拮抗劑的用途
CL2015000038A1 (es) Métodos para preparar triazolopiridinas sustituidas y compuestos intermediarios.
CR20140531A (es) Derivados de ariletinilo
MX2013005623A (es) Compuestos de 3-benciloxi-biciclico [3.1.0] hexano 4-sustituidos como antagonistas de mglur 2/3.
UY33409A (es) Moduladores no competitivos de receptores nicotinicos
CR20150028A (es) Derivados de ariletinilo
CU20150015A7 (es) Tris-(hetero)aril-pirazoles y su uso
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
CR20140130A (es) 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos
UY34489A (es) Derivados del ácido cicloalcanocarboxílico como antagonistas del receptor CXCR3
TN2013000209A1 (en) 4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists
ES2421810R1 (es) Intermedios utiles para la sintesis de fexofenadina, procedimientos para su preparacion y para la preparacion de fexofenadina
UA54879U (ru) Применение антагониста рецепторов интерлейкина-1 как средства антиоксидантного действия
UY34819A (es) Derivados de ß-aminoácido sustituidos como antagonistas del receptor CXCR3.